	US 12,421,495 B2
	Compositions and methods for selective phagocytosis of human cancer cells
Dennis E. Discher, Philadelphia, PA (US); Kyle R. Spinler, La Jolla, CA (US); and Cory Alvey, Philadelphia, PA (US)
Assigned to The Trustees of the University of Pennsylvania, Philadelphia, PA (US)
Filed by THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA (US)
Filed on Mar. 10, 2021, as Appl. No. 17/198,103.
Application 17/198,103 is a continuation of application No. 15/366,844, filed on Dec. 1, 2016, granted, now 10,946,042, issued on Mar. 16, 2021.
Claims priority of provisional application 62/376,712, filed on Aug. 18, 2016.
Claims priority of provisional application 62/261,690, filed on Dec. 1, 2015.
Prior Publication US 2021/0220401 A1, Jul. 22, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/0786 (2010.01); A61K 35/12 (2015.01); A61K 35/28 (2015.01); A61K 40/10 (2025.01); A61K 40/17 (2025.01); A61K 40/24 (2025.01); A61K 40/42 (2025.01); A61K 47/68 (2017.01); A61K 49/00 (2006.01)

CPC C12N 5/0645 (2013.01) [A61K 35/28 (2013.01); A61K 40/10 (2025.01); A61K 40/17 (2025.01); A61K 40/24 (2025.01); A61K 40/4202 (2025.01); A61K 40/4204 (2025.01); A61K 40/4257 (2025.01); A61K 47/6851 (2017.08); A61K 49/0041 (2013.01); A61K 49/0097 (2013.01); A61K 2035/124 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/55 (2023.05); C12N 2510/00 (2013.01)]

18 Claims

1. A method of enhancing phagocytic activity of a phagocytic cell toward tumor tissue in a mammal, the method comprising administering to the mammal an effective amount of a composition comprising a signal regulatory protein-alpha (SIRPα) repressed phagocytic cell bound to a targeting antibody, wherein the effective amount of the composition enhances phagocytic activity and has a therapeutic effect in the mammal, wherein the phagocytic cell is a bone marrow cell.